Marzena Krzek
Overview
Explore the profile of Marzena Krzek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krzek M, Stroobants S, Gelin P, De Malsche W, Maes D
Biomolecules
. 2022 Dec;
12(12).
PMID: 36551175
Protein self-assembly into fibrils and oligomers plays a key role in the etiology of degenerative diseases. Several pathways for this self-assembly process have been described and shown to result in...
2.
Gul T, Krzek M, Permentier H, Fraaije M, Bischoff R
Drug Metab Dispos
. 2016 Mar;
44(8):1270-6.
PMID: 26984198
Mammalian flavin-containing monooxygenases, which are difficult to obtain and study, play a major role in detoxifying various xenobiotics. To provide alternative biocatalytic tools to generate flavin-containing monooxygenases (FMO)-derived drug metabolites,...
3.
Krzek M, van Beek H, Permentier H, Bischoff R, Fraaije M
Enzyme Microb Technol
. 2015 Dec;
82:138-143.
PMID: 26672460
A generic approach for flavoenzyme immobilization was developed in which the flavin cofactor is used for anchoring enzymes onto the carrier. It exploits the tight binding of flavin cofactors to...
4.
Zabczyk M, Hondo L, Krzek M, Undas A
Blood Coagul Fibrinolysis
. 2012 Oct;
24(1):50-4.
PMID: 23037322
Low high-density lipoprotein cholesterol (HDL-C) increases cardiovascular risk, whereas its high levels protect against atherosclerosis via multiple beneficial effects. Dense and poorly lysable fibrin clot formation is observed in cardiovascular...
5.
Krzek M, Ciesla-Dul M, Zabczyk M, Undas A
Thromb Res
. 2012 Sep;
130(4):e216-21.
PMID: 22940058
Introduction: Oral contraceptives (OC) in the presence of factor V Leiden mutation (FVL) markedly increase the risk of venous thromboembolism (VTE). Little is known about the OC and FVL-related alterations...